|
(AEMSB) Positive results in stem cell treatment of heart failure
Ralph Wragg Australian Business News
22 May 2006
Sydney - Monday - May 22: (RWE Aust Business News) - Mesoblast Ltd (ASX:MSB) has had positive initial results in preclinical trials of its proprietary adult stem cells for prevention of heart failure progression following a heart attack.
Mesoblast founder Professor Silviu Itescu said that the initial positive results using adult stem cells from one universal donor to treat unrelated recipients clearly demonstrated the safety of the product and validated its plan to develop an "off-the-shelf" cell-based therapy for heart failure.
Current therapies offer only modest symptomatic benefit, do not result in rebuilding of heart muscle, and do not prevent progression of heart failure and long-term deterioration.
In contrast, in multiple preclinical models the company's proprietary adult stem cells have been shown to result in significant improvement of heart function and to prevent heart failure progression.
Mesoblast shares were up 12c to $1.43.
|
